APP to market breast cancer treatment

By Alejandra Cancino
Posted June 29, 2010 at 6:37 a.m.

Schaumburg-based APP Pharmaceuticals Inc. will begin marketing a breast cancer treatment medication in the U.S. as Anastrozole, the drug’s generic name. Anastrozole tablets, also known as Arimidex , are mainly used to treat early breast cancer in post-menopausal women.

APP’s parent company, Fresenius Kabi Pharmaceuticals Holding Inc., said the move comes after the U.S. Food and Drug Administration granted its research company permission to market the drug.

Read more about the topics in this post: , , ,

Companies in this article

Comments are closed.